Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/03/19
End: 12/29/20
Due: 12/29/21
Phase: N/A
Priority: Normal
Start: 05/30/18
End: 11/25/18
Due: 11/25/19
Phase: N/A
Priority: Normal
Start: 10/29/18
End: 07/06/19
Due: 07/06/20
Phase: N/A
Priority: Normal
Start: 06/05/17
End: 01/16/18
Due: 01/16/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis | NCT03963895 | Aronora, Inc. | user2@example.com | None | 2019-07-03 | 2020-12-29 | 2021-12-29 | - | - | 2025-07-14 |
| Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects | NCT03453060 | Aronora, Inc. | user2@example.com | None | 2018-05-30 | 2018-11-25 | 2019-11-25 | - | - | 2025-07-14 |
| Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis | NCT03612856 | Aronora, Inc. | user2@example.com | None | 2018-10-29 | 2019-07-06 | 2020-07-06 | - | - | 2025-07-14 |
| Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects | NCT03097341 | Aronora, Inc. | user2@example.com | None | 2017-06-05 | 2018-01-16 | 2019-01-16 | - | - | 2025-07-14 |